(VIANEWS) – Taiwan Semiconductor (TSM), United Therapeutics Corporation (UTHR), Opera Limited (OPRA) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Taiwan Semiconductor (TSM)
25% sales growth and 26% return on equity
Taiwan Semiconductor Manufacturing Company Limited, together with its subsidiaries, manufactures, packages, tests, and sells integrated circuits and other semiconductor devices in Taiwan, China, Europe, the Middle East, Africa, Japan, the United States, and internationally. It provides complementary metal oxide silicon wafer fabrication processes to manufacture logic, mixed-signal, radio frequency, and embedded memory semiconductors. The company also offers customer support and engineering services, as well as manufactures masks. Its products are used in high performance computing, smartphone, Internet of things, automotive, and digital consumer electronics. The company was incorporated in 1987 and is headquartered in Hsinchu City, Taiwan.
Earnings Per Share
As for profitability, Taiwan Semiconductor has a trailing twelve months EPS of $5.16.
PE Ratio
Taiwan Semiconductor has a trailing twelve months price to earnings ratio of 25.28. Meaning, the purchaser of the share is investing $25.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26%.
Volume
Today’s last reported volume for Taiwan Semiconductor is 13577100 which is 17.97% above its average volume of 11508600.
Yearly Top and Bottom Value
Taiwan Semiconductor’s stock is valued at $130.44 at 00:22 EST, way higher than its 52-week high of $115.15.
Moving Average
Taiwan Semiconductor’s value is way higher than its 50-day moving average of $100.45 and way above its 200-day moving average of $94.91.
2. United Therapeutics Corporation (UTHR)
18.7% sales growth and 17.52% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings Per Share
As for profitability, United Therapeutics Corporation has a trailing twelve months EPS of $18.13.
PE Ratio
United Therapeutics Corporation has a trailing twelve months price to earnings ratio of 11.77. Meaning, the purchaser of the share is investing $11.77 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.52%.
Moving Average
United Therapeutics Corporation’s value is below its 50-day moving average of $228.70 and under its 200-day moving average of $226.74.
Sales Growth
United Therapeutics Corporation’s sales growth is 17% for the present quarter and 18.7% for the next.
Yearly Top and Bottom Value
United Therapeutics Corporation’s stock is valued at $213.41 at 00:22 EST, way under its 52-week high of $261.54 and above its 52-week low of $204.44.
3. Opera Limited (OPRA)
16.5% sales growth and 7.37% return on equity
Opera Limited, together with its subsidiaries, provides mobile and PC web browsers. It operates in two segments, Browser and News, and Other. The company offers mobile browser products, such as Opera Mini, Opera for Android and iOS, Opera GX Mobile, and Opera Touch; PC browsers, including Opera for Computers and Opera GX; Apex Football; Opera VPN Pro; and Opera News, an AI-powered personalized news discovery and aggregation service. It also provides Opera Crypto Browser for PCs and mobile; browser-based cashback rewards; owns GameMaker Studio, a 2D gaming development platform; and GXC, a gaming portal. In addition, the company operates Opera Ads, an online advertising platform. It operates in Nigeria, Ireland, France, Germany, Spain, England, South Africa, Kenya, and internationally. The company was founded in 1995 and is headquartered in Oslo, Norway. Opera Limited is a subsidiary of Kunlun Tech Limited.
Earnings Per Share
As for profitability, Opera Limited has a trailing twelve months EPS of $0.7.
PE Ratio
Opera Limited has a trailing twelve months price to earnings ratio of 15.97. Meaning, the purchaser of the share is investing $15.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.37%.
Moving Average
Opera Limited’s value is below its 50-day moving average of $11.82 and way under its 200-day moving average of $14.17.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Opera Limited’s EBITDA is 44.74.
Yearly Top and Bottom Value
Opera Limited’s stock is valued at $11.18 at 00:22 EST, way under its 52-week high of $28.58 and way higher than its 52-week low of $6.65.
Volume
Today’s last reported volume for Opera Limited is 465709 which is 32.75% below its average volume of 692534.
4. Playa Hotels & Resorts N.V. (PLYA)
8% sales growth and 5.91% return on equity
Playa Hotels & Resorts N.V., together with its subsidiaries, owns, develops, and operates resorts in prime beachfront locations in Mexico and the Caribbean. As of December 31, 2021, it owned a portfolio of 22 resorts with 8,366 rooms located in Mexico, Jamaica, and the Dominican Republic. The company was founded in 2006 and is headquartered in Fairfax, Virginia.
Earnings Per Share
As for profitability, Playa Hotels & Resorts N.V. has a trailing twelve months EPS of $0.25.
PE Ratio
Playa Hotels & Resorts N.V. has a trailing twelve months price to earnings ratio of 33.92. Meaning, the purchaser of the share is investing $33.92 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.91%.
Sales Growth
Playa Hotels & Resorts N.V.’s sales growth is 5.9% for the ongoing quarter and 8% for the next.
